~~<i id='82047CB5EC'><strike id='82047CB5EC'><tt id='82047CB5EC'><pre id='82047CB5EC'></pre></tt></strike></i>~~

Home» explore» Wikipedia

Wikipedia

author：hotspot 2025-09-12 23:43:34 Page View：9913

Ever since Medicare was given power to negotiate prices for certain medicines, the pharmaceutical industry has argued the move will end badly for patients.

Beyond complaining about price controls and unconstitutional mandates, the key message aimed at the American public has been that innovation will suffer.

This is a familiar but tiring refrain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A letter from the executive editor: STAT UnitedHealth investigation
Next article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

focus

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

Today's health inequities arise from racist U.S. history, say experts

JasonFarley,directoroftheCenterforInfectiousDiseaseandNursingInnovationatJohnsHopkinsUniversity,atth

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Senators: Long

Sen.EdMarkeyofMassachusetts(above)andSen.JoeManchinofWestVirginiahadwordsofwarningforFDACommissioner